Proposal to amend listing in the National Immunisation Schedule – meningococcal C conjugate vaccine
23 May 2017
PHARMAC is seeking feedback on one final proposal arising from an RFP for the supply of various vaccines, following a provisional agreement with Pfizer New Zealand Limited, for the supply and funding of meningococcal C conjugate vaccine.
In summary, the proposal would result in:
- Neisvac-C(external link) remaining as the only listed meningococcal C conjugate vaccine on the National Immunisation Schedule.
- the delisting of Neisvac-C in the 10 injection pack presentation.
- a correction of the chemical name for Neisvac-C in the Pharmaceutical Schedule.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm Wednesday, 7 June 2017 to:
Fax: 04 460 4995
Post: PO Box 10 254, Wellington 6143
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.
Details of the proposal
PHARMAC proposes that from 1 July 2017 Neisvac-C would remain listed in Section I (the National Immunisation Schedule) and Part II Section H of the Pharmaceutical Schedule:
- with a correction to the chemical name;
- as a single injection pack size; and
- the 10 injection pack size would be delisted from 1 July 2017
as follows (additions in bold deletions in strikethrough):
Inj 10 mcg in 0.5 ml syringe
There would be no changes to the current restrictions in Section I or Part II of Section H of the Pharmaceutical Schedule which are:
Meningococcal C conjugate vaccine – Neisvac-C
Any of the following:
- Up to three doses and a booster every five years for patients pre- and post splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre or post solid organ transplant; or
- One dose for close contacts of meningococcal cases; or
- A maximum of two doses for bone marrow transplant patients; or
- A maximum of two doses for patients following immunosuppression*.
Note: children under seven years of age require two doses 8 weeks apart, a booster dose three years after the primary series and then five yearly.
*Immunosuppression due to steroid or other immunosuppressive therapy must be for a period of greater than 28 days.
Neisvac-C would have Sole Supply Status in both the Community and DHB Hospital settings from 1 July 2017 until 30 June 2020.
The Ministry of Health’s Immunisation Handbook(external link) provides information for vaccinators on the recommended timing of dosing for vaccines and catch up programmes.
Distribution of Vaccines unchanged
Vaccines are distributed differently to most other pharmaceuticals. The method for ordering vaccines by vaccinators would remain the same as a result of this proposal.
The vaccine would be listed with the “Xpharm” restriction with a $0.00 subsidy. An Xpharm listing means that community pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.
Background to this consultation
PHARMAC began managing the National Immunisation Schedule from 1 July 2012.
PHARMAC first issued an RFP for the supply of vaccines in June 2013, which resulted in agreements with five suppliers. Sole Supply Status for vaccines covered by those agreements expires on 30 June 2017.
In preparation for running an RFP in 2016, in 2015 PHARMAC asked suppliers submit applications to PHARMAC for:
- funding of any new or alternative brands of vaccines they may have available for supply from July 2017; and
- any proposed changes to the funding eligibility criteria for current listings and/or the National Immunisation Schedule.
PHARMAC subsequently sought clinical advice from the Immunisation Subcommittee of the Pharmacology and Therapeutics Advisory Committee (PTAC) on:
- the suitability of new vaccines recently registered by Medsafe or planned to be registered in time for 2017 supply;
- interchangeability of alternative brands; and
- possible funding eligibility criteria changes.
Following receipt of proposals, PHARMAC sought further clinical advice from the Immunisation Subcommittee, at meetings in May and November 2016, regarding refinement of the eligibility criteria for several vaccines.
PHARMAC has previously consulted on and notified of decisions relating to many vaccines resulting from the 2016 RFP:
- Immunisation Schedule Changes
- Further Immunisation Schedule Changes
The proposal in this consultation would complete the outstanding items from the RFP.
Last updated: 6 August 2020